ArticleJournal of the Endocrine Society2021
Pasireotide: A Novel Treatment for Tumor-Induced Hypoglycemia Due to Insulinoma and Non-Islet Cell Tumor Hypoglycemia.
Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- A systematic review of literature on Insulin-like growth factor-2-mediated hypoglycaemia in non-islet cell tumours.Endocrinology, diabetes & metabolism · 2024Pooled it
- Management of Non-Islet Cell Tumor Hypoglycemia Induced by Adrenal Cortical Carcinoma.JCEM case reports · 2025Article
- Article
- Adrenal cortical carcinoma with non‑islet cell tumor hypoglycemia: A case report.Oncology letters · 2025Article
- [Hypoglycemia in a patient with pleural solitary fibrous tumor and response to pasireotide]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025Article
- Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.Clinical endocrinology · 2025Review
- Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours.Endocrine oncology (Bristol, England) · 2025Article
- Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report.Frontiers in endocrinology · 2025Article
- Managing Non-islet Cell Tumor Hypoglycemia in Hepatocellular Carcinoma With Radiation Therapy.Cureus · 2024Article
- Paraneoplastic hypoglycemia: An overview for optimal clinical guidance.Metabolism open · 2024Review
- Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.World journal of gastroenterology · 2024Article
- Approach to the Patient: Insulinoma.The Journal of clinical endocrinology and metabolism · 2024Article
- Unraveling the Whipple Triad: Non-Islet Cell Tumor-Induced Hypoglycemia.JCEM case reports · 2024Article
- IGF-2-mediated hypoglycemia: a case series and review of the medical therapies for refractory hypoglycemia.Endocrinology, diabetes & metabolism case reports · 2024Article
- Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature.Clinical case reports · 2022Article
- Aggressive prolactinoma (Review).Experimental and therapeutic medicine · 2022Review
- Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.Frontiers in endocrinology · 2022Review
- Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.Cell & bioscience · 2021Review
- Resolution of Refractory Nonislet Cell Tumor Hypoglycemia Following Resection of an Abdominal Solitary Fibrous Tumor.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced hypoglycemia is a serious disorder most commonly caused by insulinoma or non-islet cell tumor hypoglycemia (NICTH). The hypoglycemia can be severe and refractory to conventional therapy, leading to significant morbidity and mortality. The objective of this work is to describe a series of challenging cases in which refractory, tumor-induced hypoglycemia was shown to respond to the use of pasireotide, a second-generation somatostatin receptor ligand. We describe the clinical and biochemical features of 3 patients with tumor-induced hypoglycemia due to an occult insulinoma, malignant insulinoma, and non-islet cell tumor hypoglycemia. In these 3 individuals, the hypoglycemia remained refractory to guideline-recommended medical therapy, such as diazoxide, nonpasireotide somatostatin analogues, and glucocorticoids. Pasireotide was substituted to attenuate the refractory hypoglycemia for each patient. The addition of pasireotide led to prompt improvement in the frequency and severity of hypoglycemic episodes for each tumor-induced hypoglycemia patient. We demonstrate the successful treatment of 3 individuals with refractory, tumor-induced hypoglycemia with pasireotide. We offer the first reported use of pasireotide for the successful treatment of nonmalignant insulinoma and non-islet cell tumor hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.